LCTX News and Press, BioTime Inc. From 09/11/23

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Gary S. Hogge, D.V.M., M.S., Ph.D., Lineage’s Senior Vice President, Clinical & Medical Affairs, w...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX ), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced the initiation of certain development activities to generate a novel hyp...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at Baird’s 2023 Global Healthc...

2023-08-10 19:29:05 ET Lineage Cell Therapeutics, Inc. (LCTX) Q2 2023 Earnings Conference Call August 10, 2023 04:30 PM ET Company Participants Ioana Hone - Head-Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gar...

2023-08-10 16:37:41 ET Lineage Cell Therapeutics press release ( NYSE: LCTX ): Q2 GAAP EPS of -$0.03 beats by $0.01 . Revenue of $3.23M (-29.8% Y/Y) beats by $1.04M . For further details see: Lineage Cell Therapeutics GAAP EPS of -$0.03 beats by $0.01, re...

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group FDA Type B Meeting Response Provides Path for New OPC1 Delivery Device Positive Topline Data Reported fro...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, followin...

Patients enrolled were diagnosed with refractory, metastatic or locally advanced, non-small cell lung cancer (NSCLC), for whom there were no other suitable treatment options Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstr...

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000 ® Index at the conclusion of...